George Sagrera, MD
Family Medicine · New Iberia, LANPI 1093772402
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 38.3% of the total. Reporting peaked in 2019 at $868 and has fallen 76.9% since, to $201 in 2025.
Across 178 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$302
- Teva Pharmaceuticals USA, Inc.$219
- Pfizer$210
- Takeda Pharmaceuticals U.S.A., Inc.$203
- Gilead$196
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,67599%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,422 |
| Amgen(2 entities) | 10 | $302 |
| Teva Pharmaceuticals USA, Inc. | 14 | $219 |
| Pfizer | 12 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $203 |
| Gilead | 2 | $196 |
| Idorsia Pharmaceuticals US Inc | 4 | $143 |
| Lilly USA, LLC | 9 | $138 |
| Corium, LLC | 8 | $112 |
| Boehringer Ingelheim | 3 | $102 |
| Jazz Pharmaceuticals Inc. | 1 | $100 |
| GSK | 6 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $82 |
| Phathom Pharmaceuticals, Inc. | 2 | $64 |
| Eisai Inc. | 2 | $44 |
| Abbott | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Novo Nordisk | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| Vertex | 1 | $29 |
| Shire North American Group Inc | 2 | $28 |
| Lundbeck LLC | 1 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,712 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 49 | $48,988 |
| EliquisApixaban | 77 | $47,511 |
| OzempicSemaglutide | 38 | $37,042 |
| FarxigaDapagliflozin Propanediol | 26 | $19,186 |
| JanuviaSitagliptin Phosphate | 17 | $15,226 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $10,759 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $8,559 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 19 | $5,495 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,058 |
| Gabapentin | 516 | $4,496 |
| Omeprazole | 367 | $2,753 |
| Atorvastatin Calcium | 283 | $1,703 |
| Tamsulosin Hcl | 160 | $1,468 |
| Cefdinir | 72 | $1,440 |
| Naproxen | 191 | $1,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $102 | $48,98849 claims |
| PfizerEliquis | $210 | $47,51177 claims |
| Novo NordiskOzempic | $34 | $37,04238 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $203 | $5,05813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in New Iberia
- Robert LahaskyNew Iberia$13K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
- Phillip ConnerSulphur$71K
- Richard JeansonneMandeville$49K
- Leonard TreanorHammond$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.